Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML). Methods: A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L. Results: The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes. Conclusions: G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.

Cite

CITATION STYLE

APA

Weng, P., Yang, S., Xu, S., Zhang, S., Wu, Y., & Chen, Y. (2023). Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor. Hematology (United Kingdom), 28(1). https://doi.org/10.1080/16078454.2023.2220521

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free